Treatment of Airway Hyperreactivity
Inventors: Dale Umetsu, Muriel Pichavant, Rosemarie DeKruyff, Everett Meyer, Stephanie Shore
Invention Types: Therapeutics
Research Areas: Allergy/Respiratory/Pulmonary Disease, Inflammation
Keywords: Disease Model, Patient CareFor More Information Contact: Meyer, Abbie
Airway hyper reactivity, a cardinal feature of asthma, results in the sudden narrowing of air passages of the lungs in response either to allergen or non-allergen stimuli. The investigators have discovered a key role of interleukin 17 (IL-17) in non-allergic asthma, and have demonstrated protection against airway hyperactivity in a model with antagonism of IL-17 signaling. By neutralizing the proinflamatory and chemotactic effects of IL-17 using an IL-17 antagonist, the development of ozone-induced airway hyper reactivity can be prevented. Ozone-induced airway hyper reactivity, in contrast to allergen-induced airway hyper reactivity, does not involve adaptive immunity or eosinophils, but rather requires natural killer T (NKT) cells and neutrophils. While IL-17 may exacerbate allergen-induced AHR, it appears to be essential in ozone-induced airway hyper reactivity.
More effective and specific treatment of non-allergen induced asthma.
Key Publications: J Exp Med. 2008 Feb 18;205(2):385-93. Epub 2008 Feb 4.
IPStatus: Pat. Pend.